Molecule Details
| InChIKey | GLLPUTYLZIKEGF-HAVVHWLPSA-N |
|---|---|
| Compound Name | Ridogrel |
| Canonical SMILES | O=C(O)CCCCO/N=C(/c1cccnc1)c1cccc(C(F)(F)F)c1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 7.25 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB01207 |
|---|---|
| Drug Name | Ridogrel |
| CAS Number | 110140-89-1 |
| Groups | experimental |
| ATC Codes | nan |
| Description | Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin. |
Categories: Acids, Acyclic Antiplatelet agents Enzyme Inhibitors Fatty Acids Fatty Acids, Volatile Gastrointestinal Agents Hematologic Agents Lipids Thromboxane-A Synthase, antagonists & inhibitors Valerates
Cross-references: BindingDB: 50003795 ChEBI: 135542 CHEMBL280728 ChemSpider: 4515025 PharmGKB: PA164746413 PubChem:5362391 PubChem:46506774 Therapeutic Targets Database: DAP000469 ZINC: ZINC000001536934